Ostrem Jill L, Starr Philip A
Department of Neurology, University of California, San Francisco, California 94143, USA.
Neurotherapeutics. 2008 Apr;5(2):320-30. doi: 10.1016/j.nurt.2008.01.002.
Pallidal deep brain stimulation (DBS) is an established treatment option for medically refractive dystonia. The mechanism by which globus pallidus pars interna (GPi) DBS improves dystonia is still unclear. Primary generalized dystonia usually responds well to this therapy, as recently confirmed in two well-designed, double-blind, controlled trials; however, predictors of outcome within this population are not well known. The role of GPi DBS in idiopathic cervical dystonia resistant to treatment with botulinum toxin, in tardive dystonia, and in some types of secondary dystonia are emerging as populations of patients who may also benefit, but outcomes are not well documented. Serious complications from this therapy are rare. Future research will likely continue to address the most appropriate programming settings for various populations of dystonia, the mechanism by which DBS affects dystonia, and the possibility of alternative brain targets that might have less associated side effects or greater efficacy than the GPi.
苍白球深部脑刺激术(DBS)是药物难治性肌张力障碍的一种既定治疗选择。内侧苍白球(GPi)DBS改善肌张力障碍的机制仍不清楚。原发性全身性肌张力障碍通常对这种治疗反应良好,最近两项精心设计的双盲对照试验证实了这一点;然而,该人群中治疗结果的预测因素尚不清楚。GPi DBS在对肉毒杆菌毒素治疗耐药的特发性颈部肌张力障碍、迟发性肌张力障碍以及某些类型的继发性肌张力障碍中的作用正在显现,这些患者群体可能也会从中受益,但治疗结果的记录并不充分。这种治疗的严重并发症很少见。未来的研究可能会继续探讨针对各种肌张力障碍人群最合适的程控设置、DBS影响肌张力障碍的机制,以及是否存在比GPi副作用更小或疗效更好的替代性脑靶点。